CheckImmune is an innovative immune biomarker CRO for preclinical and clinical programs with direct access to fresh clinical samples from patients. As a spin-off of Charité‑Universitätsmedizin Berlin hospital, we maintain strong ties to cutting-edge academic research and state-of-the art scientific innovation.

We specialize in biomarker studies for novel immunotherapeutics, including small molecules, biologics, and Advanced Therapy Medicinal Products (ATMPs), as well as immunological challenges across a broad range of medical fields.

CheckImmune is accredited to ISO 17025 and 15189 standards and operate in accordance with GCLP requirements.

Our team brings together highly regarded experts in immune biomarker analysis, data generation and interpretation.

Our services include the selection and validation of drug lead candidates, Phase 0 studies with access to fresh patient material, therapy monitoring for safety, efficacy and patient stratification, as well as data analysis and scientific and medical interpretation. At CheckImmune, we develop highly specialized immunological biomarker assays and provide end-to-end laboratory services for clinical and preclinical trials. From assay design to regulatory-grade data analysis, we help biopharma companies understand immune responses with precision.

We are a certified service provider for 10x Genomics, Olink and Bio-Techne.

With a track record of more than 90 industry-sponsored trials and 120,000 samples, we have earned an excellent international reputation.